Providence offers rare new trials for solid tumors and lung cancer
The Providence Cancer Institute of Oregon is one of only four locations worldwide recruiting patients with advanced solid tumors of any type that have relapsed or are unresponsive to treatment for a phase I dose-escalation study of IO-108 as a monotherapy and in combination with pembrolizumab, an immunotherapy.